Reuters -- H. Lundbeck A/S (Lundbeck) today announced that it has signed an agreement with Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) providing Lundbeck with exclusive rights to develop and commercialise the adenosine A2a antagonist KW-6356. Lundbeck will also have the right to further select compounds as either back-up or additional indication compounds. Adenosine A2a antagonists have potential applications in a wide range of therapeutic indications, including Parkinson’s disease. Kyowa Hakko Kirin will retain rights to develop and commercialise the compounds in Japan and the Asian region.
